All In MedTech

FDA Clearance Tracker · P030002-S035

CRYSTALENS AND TRULIGN TORIC INTRAOCULAR LENSES (IOLS)

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Mar 24, 2016 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Mar 24, 2016

Approved

Time to decision

266 days

Received Jul 2, 2015. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P030002-S035
Device name
CRYSTALENS AND TRULIGN TORIC INTRAOCULAR LENSES (IOLS)
Applicant location
Irvine, CA
Received
Jul 2, 2015
Decided
Mar 24, 2016
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Location Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P030002

Device type

Device class
Class III
Regulation
21 CFR 886.3600
Specialty
Ophthalmology

Every decision under product code MJP

FDA's approval statement

As written in FDA's record.

Approval for a manufacturing site located at Bausch & Lomb, Incorporated, 21 Park Place Boulevard North, Clearwater, Florida 33759 as an alternate manufacturing facility for the Crystalens and Trulign IOLs.

Source documents

Other decisions for Bausch & Lomb, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

3 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.